Clinical Utility of HER2/ERBB2 Copy Number Analysis by Next Generation Sequencing in Metastatic Breast Cancer

被引：0
|
作者：
Xia, Daniel [1 ]
Kuo, Frank [2 ]
Dillon, Deborah [2 ]
机构：
[1] Univ Hlth Network, Toronto, ON, Canada
[2] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
来源：
LABORATORY INVESTIGATION | 2018年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
318
引用
收藏
页码：113 / 113
页数：1
相关论文
共 50 条
  • [41] ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer
    David F. Stern
    [J]. Journal of Mammary Gland Biology and Neoplasia, 2008, 13
  • [42] ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer
    Stern, David F.
    [J]. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2008, 13 (02) : 215 - 223
  • [43] Biosimilar Therapy for ERBB2 (HER2)-Positive Breast Cancer Close Enough?
    Burstein, Harold J.
    Schrag, Deborah
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (01): : 30 - 32
  • [44] Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer
    Moutafi, Myrto
    Robbins, Charles J.
    Yaghoobi, Vesal
    Fernandez, Aileen, I
    Martinez-Morilla, Sandra
    Xirou, Vasiliki
    Bai, Yalai
    Song, Yan
    Gaule, Patricia
    Krueger, Joseph
    Bloom, Kenneth
    Hill, Salisha
    Liebler, Daniel C.
    Fulton, Regan
    Rimm, David L.
    [J]. LABORATORY INVESTIGATION, 2022, 102 (10) : 1101 - 1108
  • [45] A modified approach for evaluation of ERBB2 (HER2) gene copy number in moderately amplified invasive duct carcinomas (IDC) of the breast
    不详
    [J]. VIRCHOWS ARCHIV, 2005, 447 (02) : 363 - 363
  • [46] Targeted next generation sequencing identifies HER2 status of breast cancer patients
    Pfarr, N.
    Penzel, R.
    Endris, V.
    Noske, A.
    Budczies, J.
    Weichert, W.
    Schneeweiss, A.
    Schirmacher, P.
    Sinn, H. -P.
    Stenzinger, A.
    [J]. VIRCHOWS ARCHIV, 2017, 471 : S164 - S164
  • [47] HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
    Morsberger, Laura
    Pallavajjala, Aparna
    Long, Patty
    Hardy, Melanie
    Park, Rebecca
    Parish, Rebecca
    Nozari, Azin
    Zou, Ying S.
    [J]. CANCER CELL INTERNATIONAL, 2022, 22 (01)
  • [48] HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
    Laura Morsberger
    Aparna Pallavajjala
    Patty Long
    Melanie Hardy
    Rebecca Park
    Rebecca Parish
    Azin Nozari
    Ying S. Zou
    [J]. Cancer Cell International, 22
  • [49] ErbB2/CEP17 and total ErbB2 copy number as independent forecast factor for time to First Metastasis (TTM) and with a trastuzumab-based therapy in HER2 testing metasase breast cancer
    Fuchs, E. M.
    Koestler, W. J.
    Horvat, R.
    Hudelist, G.
    Dressler, C.
    Pfeiler, G.
    Fink-Retter, A.
    Gschwantler-Kaulich, D.
    Attems, J.
    Zielinski, C. C.
    Singer, C. F.
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2010, 70 (03) : 245 - 245
  • [50] Pan-cancer analysis of the influence of ERBB2 alteration on HER2 expression
    Lee, Taebum
    Shin, Sangwon
    Song, Heon
    Park, Seonwook
    Pereira, Sergio
    Yoo, Donggeun
    Ro, Juneyoung
    Moon, Jimin
    Cho, Soo Ick
    Ahn, Changho
    Ock, Chan-Young
    Ali, Siraj M.
    [J]. CANCER RESEARCH, 2024, 84 (06)
12345